Flagship Biosciences acquires business unit from Interpace Biosciences
BROOMFIELD — Flagship Biosciences Inc., a biotechnology company that uses artificial intelligence to analyze tissue samples, has acquired Interpace Pharma Solutions, a division of New Jersey-based Interpace Biosciences that specializes in cytogenetic, molecular pathology, and genomic profiling solutions.
Terms of the deal were not disclosed, but Flagship said the acquisition accrued after the close of an unspecified equity investment from Ampersand Capital Partners, BroadOak Capital Partners, and Research Corp. Technologies.
The acquisition allows Flagship to plant its flag in the North Carolina Research Triangle, which, like the Boulder Valley, is a hotbed for life-sciences companies.
“By combining these organizations, we create a single-source provider offering a larger range of biomarker and analytics services while maintaining and expanding the proven expertise of each laboratory,” Flagship CEO Trevor Johnson said in a prepared statement. “This will allow our customers to gain deeper insights into their clinical projects through multiple biomarker testing paradigms with cohesive data and analytical capabilities, managed in a simplified project workflow.”